NCT07413978招募中1 期
A Phase I-II, Open-label, Single-arm, Dose-escalation Clinical Trial to Evaluate the Safety and Tolerability of Human Umbilical Cord Mesenchymal Stem Cell Injection in the Treatment of Moderate to Severe Acute Respiratory Distress Syndrome
Changchun Tuohua Pharmaceutical Co., Ltd.1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2025年4月25日最近更新:
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- DLT incidence rate
研究概览
简要总结
Primary Objective: To evaluate the safety and tolerability of human umbilical cord mesenchymal stem cell injection in the treatment of moderate/severe acute respiratory distress syndrome.Secondary Objectives: To explore the efficacy and appropriate dosage of human umbilical cord mesenchymal stem cell injection in the treatment of moderate/severe acute respiratory distress syndrome.Exploratory Objective: To explore the immunogenicity and pharmacokinetic/pharmacodynamic (PK/PD) characteristics of a single dose of human umbilical cord mesenchymal stem cell injection in patients with moderate/severe acute respiratory distress syndrome.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients aged 18 to 80 years (inclusive).
- •Diagnosis of moderate or severe Acute Respiratory Distress Syndrome (ARDS) according to A New Global Definition of Acute Respiratory Distress Syndrome, with an infectious etiology.
- •No improvement after 24 hours of conventional clinical treatment (defined as a persistent PaO₂/FiO₂ ratio ≤200 mmHg or a decrease from >200 mmHg to ≤200 mmHg after 24 hours of conventional supportive therapy; for severe ARDS, this assessment period may be shortened to 8 hours).
- •Ability to fully understand the nature of the study and voluntarily provide written informed consent.
- •Willingness to comply with all study procedures and demonstrate good compliance during the study period.
- •Agreement to participate in long-term follow-up.
排除标准
- •Patients with ARDS caused by COVID-19 infection.
- •Patients currently suffering from hepatitis B, hepatitis C, active or latent tuberculosis, AIDS, syphilis, immunodeficiency disorders, or other immune system diseases.
- •Presence of severe cardiovascular diseases at screening, including:Cardiac function classification of NYHA class III or higher.Uncontrolled myocarditis or valvular disease.Malignant arrhythmia requiring pharmacological treatment.
- •Abnormal liver or renal function at screening meeting any of the following criteria:ALT or AST ≥ 5 × ULN, or total bilirubin ≥ 3 × ULN.Serum creatinine ≥ 3 × ULN, or patients currently undergoing renal replacement therapy (CRRT).
- •Patients receiving extracorporeal membrane oxygenation (ECMO) therapy at the time of screening.
- •Severe hematological abnormalities at screening, including: hemorrhagic manifestations, PTA ≤ 40% (or INR ≥ 2.0), severe anemia (Hb < 60 g/L), moderate or severe thrombocytopenia (PLT < 50 × 10^9/L), disseminated intravascular coagulation (DIC), leukemia, or other hematological abnormalities deemed ineligible for the study.
- •Severe end-stage respiratory diseases at screening.
- •Pulmonary hypertension with a pulmonary artery pressure > 70 mmHg.
- •History of deep vein thrombosis or pulmonary embolism within the 6 months prior to enrollment.
- •Patients post lung transplantation.
- •Presence of severe cardiopulmonary malformations at screening.
- •Severe psychiatric disorders.
- •Patients who are pregnant (positive pregnancy test), breastfeeding, or have a pregnancy plan, are unwilling to practice contraception during the study and for 12 months after the infusion, or are of childbearing potential and unwilling to use effective contraception.
- •Use of high-dose corticosteroids equivalent to methylprednisolone > 240 mg/day within 3 days prior to enrollment, or long-term irregular use of systemic corticosteroids for other diseases, which, in the investigator's judgment, may affect efficacy evaluation.
- •Allergy to any component of the Human Umbilical Cord Mesenchymal Stem Cell Injection (e.g., human albumin), or a history of severe allergies deemed by the investigator as unsuitable for participation.
- •Concurrent participation in another interventional clinical trial, or participation in another interventional clinical trial within the 3 months prior to screening.
- •History or current diagnosis of malignancy, or pathological confirmation of precancerous lesions.
- •Any other condition that, in the investigator's judgment, would lead to premature termination of the study, such as non-adherence to the protocol, concurrent severe illnesses requiring combined treatment, significant laboratory abnormalities, or social/family factors that could compromise the patient's safety or data collection.
研究组 & 干预措施
Human Umbilical Cord Mesenchymal Stem Cells Injection
Experimental
single-dose
干预措施: 3 vial containing a total of 1.5×10^8 cells (Biological)
Human Umbilical Cord Mesenchymal Stem Cells Injection
Experimental
single-dose
干预措施: 1 vial containing a total of 5×10^7 cells (Biological)
Human Umbilical Cord Mesenchymal Stem Cells Injection
Experimental
single-dose
干预措施: 2 vial containing a total of 1×10^8 cells (Biological)
Human Umbilical Cord Mesenchymal Stem Cells Injection
Experimental
single-dose
干预措施: 4 vial containing a total of 2×10^8 cells (Biological)
结局指标
主要结局
DLT incidence rate
时间窗: within 28 days after administration
Safety Indicator
Maximum Tolerated Dose
时间窗: Periprocedural
Safety Indicator
Any adverse events related to MSCs therapy
时间窗: within 28 days after administration
Safety Indicato
次要结局
- Incidence of Clinically Significant Changes in Vital Signs from Baseline(within 28 days after administration)
- Incidence of clinically significant changes in laboratory tests from baseline(within 28 days after administration)
- male/female tumor marker positive rate(within 28 days after administration)
- all-cause mortality(within 28 days after administration)
- Time of non-mechanical ventilation (days)(within 28 days after administration)
- Non-intensive care time (days)(within 28 days after administration)
- Time without organ failure (days)(within 28 days after administration)
- PaO2/FiO2 varies from baseline(24 hours, 3, 7, 14, 28 days after infusion of test drug)
- Arterial blood gas analysis (pH, PaO _ 2, PaCO _ 2, Lac) changed from baseline(24 hours, 3, 7, 14, 28 days after infusion of test drug)
- Lung injury score changes from baseline(Days 7, 14, 28)
- Sequential organ failure score changes from baseline(Days 3, 7, 14, 28)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Androgenic AlopeciaNCT07373054Fujian Medical University Union Hospital18
招募中
1 期
First in Human Study of SIM0610 in Solid TumorsColorectal CancerHepatocellular CarcinomaNon-Small Cell Lung CancerNCT07348211Jiangsu Simcere Pharmaceutical Co., Ltd.260
尚未招募
1 期
68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate CancerNCT07310355Chengdu StarRay Therapeutics Co., Ltd49
招募中
2 期
First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
(ADCElerate 1)2024-516900-41-00ADCendo ApS105
尚未招募
2 期
A Multicenter, Randomized, Open-Label, Controlled Clinical Trial of Intrauterine Injection of Recombinant Humanized Type III Collage in the Fertility-Sparing Treatment of Endometrial Cancer or Atypical HyperplasiaNCT07377734Wang Jianliu30